Immunova to Acquire AlphaTON Subsidiary Iox Therapeutics
Immunova has moved to acquire AlphaTON's cancer-treatment subsidiary, Iox Therapeutics, in a deal that signals a stra...
Determine whether a 6-month or 12-month fund is right for you by assessing income stability, essential expenses, and personal risk appetite.
15,911 articlesImmunova has moved to acquire AlphaTON's cancer-treatment subsidiary, Iox Therapeutics, in a deal that signals a stra...
OpenAI CEO Sam Altman and Anthropic CEO Dario Amodei avoided a handshake at the India AI Impact Summit, signaling a w...
When a crypto exchange missteps, the ripple is felt beyond traders. This article explores why south korean lawmakers ...
Ethereum faces a pivotal juncture as it tests critical support while the longer-term trend remains bearish. Traders w...
Many people chase a $2 million retirement nest egg, but a personalized target matters more. This guide breaks down ho...
Investing in Nexpoint Residential (NXRT) hinges on understanding earnings beyond headline numbers. This guide breaks ...
Ethereum broke above the $2,000 mark, signaling a potential rebound after a tough month. Analysts weigh ethereum pric...
As GoodRx navigates evolving discount dynamics and a changing membership model, the 2025 earnings picture will hinge ...
eBay announced an 800-job cut across its operations, about 6% of headcount, days after closing a $1.2 billion cash de...
Ripple ETFs post a tepid week of inflows while XRP clings close to $1.40, as traders wrestle with whether the initial...
A wave of institutional interest is reshaping AI infrastructure stocks. This guide explains why capital is flowing in...
Unpack the essential takeaways from MASS's hypothetical Q4 2025 earnings. Learn how to read the transcript, spot marg...